This trial is intended to examine the basic pharmacokinetics of BI 456906 and total \[14C\]-radioactivity, including mass balance, excretion pathways and metabolism following a single subcutaneous (SC) dose of BI 456906 (C-14) in (otherwise) healthy male volunteers with normal body weight, overweight or obesity.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
6
BI 456906 (C-14)
ICON
Groningen, Netherlands
Fraction of [14C]-radioactivity excreted in urine expressed as percentage of the administered dose over the time interval from 0 to the last quantifiable time point (fe_urine, 0-tz)
Time frame: up to 7 weeks
Fraction of [14C]-radioactivity excreted in faeces expressed as percentage of the administered dose over the time interval from 0 to the last quantifiable time point (fe_faeces, 0-tz)
Time frame: up to 7 weeks
Maximum measured concentration of the analyte (Cmax)
Time frame: up to 22 days
Area under the concentration-time curve of the analyte over the time interval from 0 to the last quantifiable time point (AUC0-tz)
Time frame: up to 22 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.